Here's Why I Bought This Recent Genetics IPO
Consumer genetics testing company 23andMe Holding (NASDAQ: ME) recently went public via special purpose acquisition company merger, and longtime Fool.com contributor Matt Frankel, CFP, jumped at the opportunity to add shares to his portfolio. In this Fool Live video clip, recorded on Sept. 15, Frankel discusses why he's so excited about 23andMe's future with fellow contributors Danny Vena and Jason Hall.
Source Fool.com
